Announcement: FDA-Cleared AI Tool EchoNext Enables ECG-Based Heart Disease Screening

Last updated: 12/08/2026 19:30

0 Min Read

Pathway Labs' EchoNext, an FDA-cleared artificial intelligence tool, enables detection of structural heart disease using standard electrocardiogram data. Integration into the OpenEvidence platform is expected to expand access to cardiac screening across healthcare systems. — Photo by Jair Lázaro on Unsplash (Unsplash License)

1 min read|45 words

EchoNext, an FDA-cleared AI tool from Pathway Labs, now enables rapid detection of structural heart disease using standard ECG data. The technology integrates into OpenEvidence, expanding access to cardiac screening across healthcare systems. Faster diagnosis without additional imaging.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: FDA-Cleared AI Tool EchoNext Enables ECG-Based Heart Disease Screening →

Share This Article

ByProf. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Announcement: FDA-Cleared AI Tool EchoNext Enables ECG-Based Heart Disease Screening

Submit Your Paper →

Medical Groups Warn Gender-Affirming Care Bans Undermine Child Safety, Not Protect It

How US Hospital Operators Exploit Emergency Care Loopholes While Generating Millions

First oral drug shows promise in childhood achondroplasia: Phase 3 trial results

Submit Your Paper to GMJ

Company

You Might Also Like